Business
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
Company to Host Conference Call, August 7, 2023, at 4:30 p.m. ET SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Company to Host Conference Call, August 7, 2023, at 4:30 p.m. ET\nSAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on August 7. Title:Capricor Therapeutics Second Quarter 2023 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, August 7, 2023Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-888-886-7786International: 1-416-764-8658 Conference ID: 02236204Participants can use guest dial-in numbers above and be answered by an operator or click the Call me™ link for instant telephone access to the event.Webcast:Webcast Link - Click Here A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Further, Capricor has entered into a partnership for the exclusive commercialization and distribution of CAP-1002 for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results ...